Finch Therapeutics Group, Inc. (FNCH)
OTCMKTS
· Delayed Price · Currency is USD
12.50
-0.75 (-5.66%)
Mar 5, 2026, 10:11 AM EST
Finch Therapeutics Group Employees
Finch Therapeutics Group had 1 employees as of December 31, 2023. The number of employees decreased by 17 or -94.44% compared to the previous year.
Employees
1
Change (1Y)
-17
Growth (1Y)
-94.44%
Revenue / Employee
n/a
Profits / Employee
-$14,167,000
Market Cap
21.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1 | -17 | -94.44% |
| Dec 31, 2022 | 18 | -171 | -90.48% |
| Dec 31, 2021 | 189 | 58 | 44.27% |
| Dec 31, 2020 | 131 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Provectus Biopharmaceuticals | 6 |
| Oncotelic Therapeutics | 26 |
| Anebulo Pharmaceuticals | 3 |
| Inhibitor Therapeutics | 9 |
| Zeo ScientifiX | 20 |
| Harvard Apparatus Regenerative Technology | 8 |
| HOOKIPA Pharma | 87 |
| ZIVO Bioscience | 7 |
Finch Therapeutics Group News
- 11 months ago - Arquitos Capital's Largest Holdings For Q1 2025 - Seeking Alpha
- 1 year ago - Finch Announces Delisting from Nasdaq and SEC Deregistration - GlobeNewsWire
- 2 years ago - Finch Announces Reverse Stock Split of Common Stock - GlobeNewsWire
- 3 years ago - Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 years ago - Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement - GlobeNewsWire
- 3 years ago - Finch Therapeutics: Why This Finch Could Fly - An Asymmetric Risk/Reward Opportunity - Seeking Alpha
- 3 years ago - Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 years ago - Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets - GlobeNewsWire